Is Sudarshan Pharma overvalued or undervalued?

Nov 09 2025 08:12 AM IST
share
Share Via
As of November 7, 2025, Sudarshan Pharma is considered overvalued with a PE ratio of 41.79 and an EV to EBITDA of 22.51, significantly higher than its peers, and has underperformed the Sensex with a year-to-date return of -37.08%.
As of 7 November 2025, Sudarshan Pharma's valuation grade has moved from fair to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 41.79, an EV to EBITDA of 22.51, and a ROE of 12.65%.

In comparison to its peers, Sudarshan Pharma's PE ratio is significantly higher than Sun Pharma's 35.17 and Cipla's 22.33, while its EV to EBITDA is also elevated compared to Cipla's 5.58. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -37.08% compared to the Sensex's 6.50%, further reinforcing the notion of overvaluation.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News